Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

OBJECTIVE: To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in patients with multiple sclerosis (MS). MET...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neurology
Main Authors: Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R., Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans, Christophe, Ho, Pei-Ran, Campbell, Nolan
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7010325/
https://ncbi.nlm.nih.gov/pubmed/31515290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000008243
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki